TOLERANZIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.528 SEK | +5.81% |
|
+3.94% | +23.36% |
| 02-23 | Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| 02-23 | Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 27.59M 2.53M 202M | Sales 2022 | 35.37M 3.25M 259M | Capitalization | 124M 11.34M 904M |
|---|---|---|---|---|---|
| Net income 2021 | -6M -551K -43.92M | Net income 2022 | -8M -734K -58.56M | EV / Sales 2021 | 1.98 x |
| Net cash position 2021 | 75.43M 6.92M 552M | Net cash position 2022 | 33.09M 3.04M 242M | EV / Sales 2022 | 2.56 x |
| P/E ratio 2021 |
-13.3
x | P/E ratio 2022 |
-14.6
x | Employees | 12 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 82.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +5.81% | ||
| 1 week | +3.94% | ||
| Current month | -1.86% | ||
| 1 month | -1.86% | ||
| 3 months | -15.65% | ||
| 6 months | +42.70% | ||
| Current year | +23.36% |
1 week
0.48
0.57
1 month
0.450.57
Current year
0.370.66
1 year
0.351.00
3 years
0.352.07
5 years
0.357.76
10 years
0.3512.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | - | |
Thomas Pålsson
DFI | Director of Finance/CFO | 72 | 29/10/23 |
| Chief Tech/Sci/R&D Officer | 65 | 16/01/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 31/12/19 | |
| Director/Board Member | 64 | 31/12/20 | |
Maarten Kraan
BRD | Director/Board Member | 63 | 31/12/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.528 | +5.81% | 256,694 |
| 25/04/24 | 0.499 | -0.20% | 210,447 |
| 24/04/24 | 0.5 | -1.96% | 86,860 |
| 23/04/24 | 0.51 | +2.00% | 198,673 |
| 22/04/24 | 0.5 | -1.57% | 87,225 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:12 pm
More quotes
Toleranzia AB is a Sweden-based company engaged in the development of a platform technology for treatment of autoimmune diseases. The Company's main project is aimed against an autoimmune nerve-muscle disease and myasthenia gravis. The Companyâs platform technology enables the development of therapies targeting the cause of the disease, which in the current situation is the usual treatment.
Calendar
19/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +23.36% | 9.49M | |
| +4.36% | 32.47B | |
| +16.51% | 7.45B | |
| +22.93% | 3.89B | |
| -16.29% | 3.17B | |
| -25.96% | 1.28B | |
| -36.14% | 1.09B | |
| -35.42% | 902M | |
| -0.13% | 893M | |
| -24.12% | 857M |
- Stock Market
- Equities
- TOL Stock
